Tagged: Pinghua Liu

Two Groups Awarded BWF Travel Grants

March 14th, 2011 in Allen, Karen, Front Page, Graduate, Grants & Funding, Liu, Pinghua, Research

Burroughs Wellcome Fund

The Burroughs Wellcome Fund (BWF) uses Collaborative Research Travel Grants to facilitate biomedical research among laboratories in the US and abroad. This February, two Chemistry groups received these competitive awards.

One of the grants will support Professor Pinghua Liu and his graduate student, Jinzhao Shen, to go to Beijing to work in the laboratory of Professor Xiaoping Chen of the Chinese Academy of Sciences. They will collaborate with Professor Chen’s group to develop new anti-microbial drugs, focusing initially on new anti-malaria drugs for multi-drug resistant strains. Specifically, they will build marine natural product libraries and screen them for anti-malaria activities.

The second grant will support graduate student, Daniel Saltzberg, in the Allen Group. Mr. Saltzberg will work with Dr. Hiro Tsuruta’s group at the Stanford Synchrotron Radiation Lightsource to probe the specific interactions governing ligand binding in a large superfamily of metabolic enzymes. These studies will provide insight into the evolution of functional diversity in this superfamily.

Tagged , , , , ,

NIH funds Pinghua Liu and his group to perform mechanistic studies of enzymes in isoprenoid biosynthesis

May 21st, 2010 in Faculty, Front Page, Grants & Funding, Liu, Pinghua, NIH

Professor Pinghua Liu

Professor Pinghua Liu

The goal of this award ($1.9 million over 5 years – 2010-2015) is to characterize the mechanism of a key enzyme in the deoyxylulose biosynthetic pathway as well as identify its key partner proteins. This pathway, identified only in bacteria and plants, produces the required compounds for isoprenoid synthesis. The results of this work could eventually lead to new broad-spectrum antibiotics or toward more efficient bioengineering based isoprenoid production. The work has developed an enzyme preparation that is many times more active than those previously reported, providing a crucial piece to illuminating enzymes. These isoprenoid biosynthetic studies will guide the development of mechanism- based inhibitors of the DXP pathway enzymes, which can be used as broad-spectrum antibiotics. The public health benefit will result from the development of effective new treatments for drug-resistant strains of pathogens (e.g., tuberculosis), currently of increasing concern worldwide.